5 Stocks Pushing The Health Care Sector Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 30 points (-0.2%) at 14,005 as of Wednesday, Feb. 20, 2013, 12:04 PM ET. The NYSE advances/declines ratio sits at 991 issues advancing vs. 1,875 declining with 138 unchanged.

The Health Care sector currently sits down 0.1% versus the S&P 500, which is down 0.5%. On the negative front, top decliners within the sector include Life Technologies ( LIFE), down 7.4%, Thermo Fisher Scientific ( TMO), down 2.5%, Medtronic ( MDT), down 2.2%, UnitedHealth Group ( UNH), down 1.8% and Cigna ( CI), down 1.0%. Top gainers within the sector include Pharmacyclics Incorporated ( PCYC), up 2.4%, Express Scripts ( ESRX), up 1.9%, Alexion Pharmaceuticals ( ALXN), up 1.4%, Amgen ( AMGN), up 1.1% and Teva Pharmaceutical Industries ( TEVA), up 0.7%.

TheStreet Ratings group would like to highlight 5 stocks pushing the sector lower today:

5. Boston Scientific ( BSX) is one of the companies pushing the Health Care sector lower today. As of noon trading, Boston Scientific is down $0.14 (-1.9%) to $7.36 on average volume Thus far, 8.5 million shares of Boston Scientific exchanged hands as compared to its average daily volume of 20.7 million shares. The stock has ranged in price between $7.34-$7.54 after having opened the day at $7.48 as compared to the previous trading day's close of $7.50.

Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. Boston Scientific has a market cap of $10.4 billion and is part of the health services industry. The company has a P/E ratio of 11.4, below the S&P 500 P/E ratio of 17.7. Shares are up 31.6% year to date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Boston Scientific a buy, no analysts rate it a sell, and 15 rate it a hold.

TheStreet Ratings rates Boston Scientific as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share. Get the full Boston Scientific Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you liked this article you might like

Baxter International, Becton Dickinson, Boston Scientific: Cramer's Top Takeaways

Perils of Politics: Cramer's 'Mad Money' Recap (Monday 7/31/17)

These Stocks Are Ready to Reverse Course

Modi's Visit to Meet Trump Focuses Big Spotlight on the H-1B Visa Debate

Cramer: These Sectors Look Bullish (Part III)